Search

Your search keyword '"Kanduri, Swetha R."' showing total 37 results
Start Over Author "Kanduri, Swetha R."
37 results on '"Kanduri, Swetha R."'

3. Urinary Vacuolar Casts Are a Unique Type of Casts in Advanced Proteinuric Glomerulopathies

Author

Rosenbloom, Sarah, primary, Ramanand, Akanksh, additional, Stark, Anabella, additional, Varghese, Vipin, additional, Chalmers, Dustin, additional, Au-Yeung, Nathan, additional, Kanduri, Swetha R., additional, Lukitsch, Ivo, additional, Poloni, Jose Antonio T., additional, Keitel, Elizete, additional, Franz, Ana Paula, additional, Martínez-Figueroa, Carlos, additional, Sarkar, Abhirup, additional, Alix-Arbatin, Maia C., additional, Fogo, Agnes B., additional, Buchkremer, Florian, additional, Seltzer, Jay R., additional, and Velez, Juan Carlos Q., additional

Published
2024
Full Text
View/download PDF

5. Responsiveness to Vasoconstrictor Therapy in Hepatorenal Syndrome Type 1

Author

Velez, Juan Carlos Q., primary, Karakala, Nithin, additional, Tayebi, Kasra, additional, Wickman, Terrance J., additional, Mohamed, Muner M. B., additional, Kovacic, Rosemary A., additional, Therapondos, George, additional, Kanduri, Swetha R., additional, Allegretti, Andrew S., additional, Belcher, Justin M., additional, Regner, Kevin R., additional, and Wentowski, Cathy, additional

Published
2023
Full Text
View/download PDF

7. Immobilization-associated hypercalcaemia in patients with malignancy in the hospital setting.

Author

Kanduri, Swetha R, Stark, Anabella, and Velez, Juan Carlos Q

Subjects
*CHRONIC kidney failure, *ACUTE kidney failure, *BONE resorption, *BONE growth, *BONE metastasis
Abstract

This article discusses the occurrence of immobilization-associated hypercalcaemia (Immob-HCa) in patients with malignancy in the hospital setting. The study conducted a retrospective review of medical records over a 3-year period and identified 145 patients with in-hospital malignancy-associated hypercalcaemia (MAH). The main causes of MAH were bone metastasis, multiple myeloma, elevated parathyroid hormone (PTH), PTH-related peptide (PTHrP), and elevated calcitriol. Immob-HCa accounted for approximately 4% of in-hospital MAH cases. The study suggests that early mobilization should be encouraged in the management of Immob-HCa. However, the study has limitations due to its retrospective nature and small sample size. [Extracted from the article]

Published
2024
Full Text
View/download PDF

8. Renal manifestations of hepatitis E among immunocompetent and solid organ transplant recipients

Author

Kovvuru, Karthik, primary, Carbajal, Nicholas, additional, Pakanati, Abhinandan Reddy, additional, Thongprayoon, Charat, additional, Hansrivijit, Panupong, additional, Boonpheng, Boonphiphop, additional, Pattharanitima, Pattharawin, additional, Nissaisorakarn, Voravech, additional, Cheungpasitporn, Wisit, additional, and Kanduri, Swetha R, additional

Published
2022
Full Text
View/download PDF

9. In-hospital mortality of hepatorenal syndrome in the United States: Nationwide inpatient sample

Author

Kaewput, Wisit, primary, Thongprayoon, Charat, additional, Dumancas, Carissa Y, additional, Kanduri, Swetha R, additional, Kovvuru, Karthik, additional, Kaewput, Chalermrat, additional, Pattharanitima, Pattharawin, additional, Petnak, Tananchai, additional, Lertjitbanjong, Ploypin, additional, Boonpheng, Boonphiphop, additional, Wijarnpreecha, Karn, additional, Zabala Genovez, Jose L, additional, Vallabhajosyula, Saraschandra, additional, Jadlowiec, Caroline C, additional, Qureshi, Fawad, additional, and Cheungpasitporn, Wisit, additional

Published
2021
Full Text
View/download PDF

12. Incidence and Characteristics of Kidney Stones in Patients on Ketogenic Diet: A Systematic Review and Meta-Analysis

Author

Acharya, Prakrati, primary, Acharya, Chirag, additional, Thongprayoon, Charat, additional, Hansrivijit, Panupong, additional, Kanduri, Swetha R., additional, Kovvuru, Karthik, additional, Medaura, Juan, additional, Vaitla, Pradeep, additional, Garcia Anton, Desiree F., additional, Mekraksakit, Poemlarp, additional, Pattharanitima, Pattharawin, additional, Bathini, Tarun, additional, and Cheungpasitporn, Wisit, additional

Published
2021
Full Text
View/download PDF

13. Glucarpidase for Treatment of High-Dose Methotrexate Toxicity

Author

Gupta, Shruti, Kaunfer, Sarah A., Chen, Kevin L., Dias, Julie-Alexia, Vijayan, Anitha, Rajasekaran, Arun, Prosek, Jason M., Truong, Huong L., Wood, Anthony, Bassil, Claude, Renaghan, Amanda D., Shah, Chintan V., Zhang, Jingjing, Glezerman, Ilya, Carlos, Christopher, Kelly, Katherine, Passero, Christopher J., Drappatz, Jan, Abudayyeh, Ala, Shin, Daniel Sanghoon, Sperati, C. John, Yelvington, Bradley J., Kanduri, Swetha R., Neyra, Javier A., Edmonston, Daniel, Shirali, Anushree C., Bansal, Anip, Geara, Abdallah, Mithani, Zain, Ziolkowski, Susan L., Rashidi, Arash, Jakubowski, Jonathan, Pujari, Ashwini, Bond, David A., Dotson, Emily, Wall, Sarah, Patton, John, Barreto, Jason N., Hermann, Sandra M., Sheikh, Mohammad S., Baz, Rachid, Lee, Jamie, Lucchesi, Nicholas, Kolman, Michael, Rasheed, Muhammad Ahsan, Afzal, Afsheen, Kang, Dasol, Mahesh, Amrita, Hsu, Raymond, Nicolaysen, Anthony, Tefera, Kibrewessen, Schretlen, Claire, Miller, Ryan M., Velez, Juan Carlos, Flannery, Alexander H., Aklilu, Abinet M., Anand, Shuchi, Chandrasekhara, Soniya, Donley, Vicki, Patel, Ashka, Ni, Jian, Krishnamurthy, Shobana, Ali, Rafia, Yilmam, Osman A., Wells, Sophia L., Ortega, Jessica L., Green-Lingren, Olivia L., Leaf, Rebecca K., Sise, Meghan E., Nayak, Lakshmi, LaCasce, Ann, Leung, Nelson, and Leaf, David E.

Abstract

•In patients with MTX-AKI, glucarpidase was associated with a higher adjusted odds of kidney recovery and faster time-to-kidney recovery.•Glucarpidase receipt was also associated with a lower adjusted odds of grade ≥2 transaminitis and grade ≥2 neutropenia.

Published
2025
Full Text
View/download PDF

14. Outcomes of Kidney Transplantation in Fabry Disease: A Meta-Analysis

Author

Suarez, Maria L. Gonzalez, primary, Thongprayoon, Charat, additional, Hansrivijit, Panupong, additional, Medaura, Juan, additional, Vaitla, Pradeep, additional, Mao, Michael A., additional, Bathini, Tarun, additional, Boonpheng, Boonphiphop, additional, Kanduri, Swetha R., additional, Kovvuru, Karthik, additional, Basu, Arpita, additional, and Cheungpasitporn, Wisit, additional

Published
2020
Full Text
View/download PDF

15. Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review

Author

Gonzalez Suarez, Maria L, primary, Thongprayoon, Charat, additional, Hansrivijit, Panupong, additional, Kovvuru, Karthik, additional, Kanduri, Swetha R, additional, Aeddula, Narothama R, additional, Pivovarova, Aleksandra I, additional, Chewcharat, Api, additional, Bathini, Tarun, additional, Mao, Michael A, additional, Basu, Arpita, additional, and Cheungpasitporn, Wisit, additional

Published
2020
Full Text
View/download PDF

16. The impact of race on hospitalization outcomes for goodpasture’s syndrome in the United States: nationwide inpatient sample 2003–2014

Author

Cheungpasitporn, Wisit, primary, Thongprayoon, Charat, additional, Mao, Michael A., additional, Boonpheng, Boonphiphop, additional, Bathini, Tarun, additional, Vallabhajosyula, Saraschandra, additional, Medaura, Juan, additional, Chewcharat, Api, additional, Kanduri, Swetha R., additional, Kovvuru, Karthik, additional, Salim, Sohail Abdul, additional, and Kaewput, Wisit, additional

Published
2020
Full Text
View/download PDF

20. Hospitalizations for Acute Salicylate Intoxication in the United States

Author

Thongprayoon, Charat, primary, Petnak, Tananchai, additional, Kaewput, Wisit, additional, Mao, Michael A., additional, Kovvuru, Karthik, additional, Kanduri, Swetha R., additional, Boonpheng, Boonphiphop, additional, Bathini, Tarun, additional, Vallabhajosyula, Saraschandra, additional, Pivovarova, Aleksandra I., additional, Brar, Himmat S., additional, Medaura, Juan, additional, and Cheungpasitporn, Wisit, additional

Published
2020
Full Text
View/download PDF

21. Impact of rhabdomyolysis on outcomes of hospitalizations for heat stroke in the United States

Author

Thongprayoon, Charat, primary, Petnak, Tananchai, additional, Kanduri, Swetha R., additional, Kovvuru, Karthik, additional, Cheungpasitporn, Wisit, additional, Boonpheng, Boonphiphop, additional, Chewcharat, Api, additional, Bathini, Tarun, additional, Medaura, Juan, additional, Vallabhajosyula, Saraschandra, additional, and Kaewput, Wisit, additional

Published
2020
Full Text
View/download PDF

23. Epidemiology of cannabis use and associated outcomes among kidney transplant recipients: A meta‐analysis

Author

Vaitla, Pradeep K., primary, Thongprayoon, Charat, additional, Hansrivijit, Panupong, additional, Kanduri, Swetha R., additional, Kovvuru, Karthik, additional, Rivera, Franco H. Cabeza, additional, Cato, Liam D., additional, Garla, Vishnu, additional, Watthanasuntorn, Kanramon, additional, Wijarnpreecha, Karn, additional, Chewcharat, Api, additional, Aeddula, Narothama Reddy, additional, Bathini, Tarun, additional, Koller, Felicitas L., additional, Matemavi, Praise, additional, and Cheungpasitporn, Wisit, additional

Published
2020
Full Text
View/download PDF

28. Impact of ANCA-Associated Vasculitis on Outcomes of Hospitalizations for Goodpasture’s Syndrome in the United States: Nationwide Inpatient Sample 2003–2014

Author

Thongprayoon, Charat, primary, Kaewput, Wisit, additional, Boonpheng, Boonphiphop, additional, Ungprasert, Patompong, additional, Bathini, Tarun, additional, Srivali, Narat, additional, Vallabhajosyula, Saraschandra, additional, Castaneda, Jorge L., additional, Monga, Divya, additional, Kanduri, Swetha R., additional, Medaura, Juan, additional, and Cheungpasitporn, Wisit, additional

Published
2020
Full Text
View/download PDF

29. Incidence and impact of acute kidney injury on patients with implantable left ventricular assist devices: a Meta-analysis

Author

Thongprayoon, Charat, primary, Lertjitbanjong, Ploypin, additional, Cheungpasitporn, Wisit, additional, Hansrivijit, Panupong, additional, Fülöp, Tibor, additional, Kovvuru, Karthik, additional, Kanduri, Swetha R., additional, Davis, Paul W., additional, Vallabhajosyula, Saraschandra, additional, Bathini, Tarun, additional, Watthanasuntorn, Kanramon, additional, Prasitlumkum, Narut, additional, Chokesuwattanaskul, Ronpichai, additional, Ratanapo, Supawat, additional, Mao, Michael A., additional, and Kashani, Kianoush, additional

Published
2020
Full Text
View/download PDF

30. Epidemiology of cannabis use and associated outcomes among kidney transplant recipients: A meta‐analysis.

Author

Vaitla, Pradeep K., Thongprayoon, Charat, Hansrivijit, Panupong, Kanduri, Swetha R., Kovvuru, Karthik, Rivera, Franco H. Cabeza, Cato, Liam D., Garla, Vishnu, Watthanasuntorn, Kanramon, Wijarnpreecha, Karn, Chewcharat, Api, Aeddula, Narothama Reddy, Bathini, Tarun, Koller, Felicitas L., Matemavi, Praise, and Cheungpasitporn, Wisit

Subjects
KIDNEY transplantation, MARIJUANA, DRUG abuse, BIOLOGICAL dressings
Abstract

Objective: Cannabis is the most commonly used recreational drug in the United States, and transplant acceptability for cannabis using candidates varies among transplant centers. However, the prevalence and impact of cannabis use on outcomes of kidney transplant recipients remain unclear. This study aimed to summarize the prevalence and impact of cannabis use on outcomes after kidney transplantation. Methods: A literature search was performed using Ovid MEDLINE, EMBASE, and The Cochrane Library Databases from inception until September 2019 to identify studies assessing the prevalence of cannabis use among kidney transplant recipients, and reported adverse outcomes after kidney transplantation. Effect estimates from the individual studies were obtained and combined utilizing random‐effects, generic inverse variance method of DerSimonian‐Laird. Results: A total of four cohort studies with a total of 55 897 kidney transplant recipients were enrolled. Overall, the pooled estimated prevalence of cannabis use was 3.2% (95% CI 0.4%‐20.5%). While the use of cannabis was not significantly associated with all‐cause allograft failure (OR = 1.31, 95% CI 0.70‐2.46) or mortality (OR = 1.52, 95% CI 0.59‐3.92), the use of cannabis among kidney transplant recipients was significantly associated with increased death‐censored graft failure with pooled OR of 1.72 (95% CI 1.13‐2.60). Conclusions: The overall estimated prevalence of cannabis use among kidney transplant recipients is 3.2%. The use of cannabis is associated with increased death‐censored graft failure, but not mortality after kidney transplantation. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. The impact of race on hospitalization outcomes for goodpasture’s syndrome in the United States: nationwide inpatient sample 2003–2014

Author

Cheungpasitporn, Wisit, Thongprayoon, Charat, Mao, Michael A., Boonpheng, Boonphiphop, Bathini, Tarun, Vallabhajosyula, Saraschandra, Medaura, Juan, Chewcharat, Api, Kanduri, Swetha R., Kovvuru, Karthik, Salim, Sohail Abdul, and Kaewput, Wisit

Abstract

ABSTRACTBackgroundGoodpasture’s syndrome is a rare and life-threatening autoimmune disease. While Goodpasture’s syndrome is well described in Caucasian and Asian populations, its prevalence and outcomes among African American and Hispanic populations are unclear. We conducted this study to assess the impacts of race on hospital outcomes among patients with Goodpasture’s syndrome.MethodsThe National Inpatient Sample database was used to identify hospitalized patients with a principal diagnosis of Goodpasture’s syndrome from 2003 to 2014. Goodpasture’s syndrome patients were grouped based on their race. The differences in-hospital supportive care for organ failure and outcomes between Caucasian, African American, and Hispanic Goodpasture’s syndrome patients were assessed using logistic regression analysis.ResultsNine hundred and sixty-four patients were hospitalized with a primary diagnosis of Goodpasture’s syndrome. Of these, 786 were included in the analysis: 622 (79%) were Caucasian, 73 (9%) were African American, and 91 (12%) were Hispanic. Hispanics had significantly lower use of plasmapheresis. The use for mechanical ventilation, noninvasive ventilation support, and renal replacement therapy in African Americans and Hispanics were comparable to Caucasians. There was no significant difference in organ failure, sepsis, and in-hospital mortality between African Americans and Caucasians. In contrast, Hispanics had higher in-hospital mortality than Caucasians but similar risk of organ failure and sepsis.ConclusionAfrican American and Hispanic populations account for 9% and 12% of hospitalizations for Goodpasture’s syndrome, respectively. While there is no significant difference in in-hospital mortality between African Americans and Caucasians, Hispanics with Goodpasture’s syndrome carry a higher in-hospital mortality compared to Caucasians.

Published
2021
Full Text
View/download PDF

32. Lithium: Weighing potential risks of nephrotoxicity against benefits.

Author

Kovvuru, Karthik, Kanduri, Swetha R., Pivovarova, Aleksandra, Thongprayoon, Charat, and Cheungpasitporn, Wisit

Subjects
*THERAPEUTIC use of lithium, *NEPHROTOXICOLOGY, *GLYCOGEN synthase kinase, *ACUTE kidney failure, *TREMOR, *FOCAL segmental glomerulosclerosis
Abstract

Bipolar disorder is a psychiatric disorder, most often characterized by episodes of mania, hypomania, and depression. Small cohort studies have demonstrated beneficial effects of lithium in increasing production of G-CSF factors, augmenting G-CSF effects, modulating peripheral neutrophils, and macrophages; therefore, suggesting therapeutic use in patients with neutropenia.2 Apart from the beneficial effects, patients on lithium therapy are faced with some short- and long-term challenges. A recent nationwide study by Kessing et al in Danish cohort reported no increased rate of end-stage renal disease in patients with increasing lithium prescriptions compared to patients on antipsychotics. [Extracted from the article]

Published
2021
Full Text
View/download PDF

33. Outcomes of Kidney Transplantation in Fabry Disease: A Meta-Analysis.

Author

Suarez, Maria L. Gonzalez, Thongprayoon, Charat, Hansrivijit, Panupong, Medaura, Juan, Vaitla, Pradeep, Mao, Michael A., Bathini, Tarun, Boonpheng, Boonphiphop, Kanduri, Swetha R., Kovvuru, Karthik, Basu, Arpita, and Cheungpasitporn, Wisit

Subjects
ANGIOKERATOMA corporis diffusum, KIDNEY transplantation, META-analysis, LYSOSOMAL storage diseases, CENTRAL nervous system, GENE therapy
Abstract

Background: Fabry disease (FD) is a rare X-linked lysosomal storage disorder with progressive systemic deposition of globotriaosylceramide, leading to life-threatening cardiac, central nervous system, and kidney disease. Current therapy involves symptomatic medical management, enzyme replacement therapy (ERT), dialysis, kidney transplantation, and, more recently, gene therapy. The aim of this systematic review was to assess outcomes of kidney transplantation among patients with FD. Methods: A comprehensive literature review was conducted utilizing MEDLINE, EMBASE, and Cochrane Database, from inception through to 28 February 2020, to identify studies that evaluate outcomes of kidney transplantation including patient and allograft survival among kidney transplant patients with FD. Effect estimates from each study were extracted and combined using the random-effects generic inverse variance method of DerSimonian and Laird. Results: In total, 11 studies, including 424 kidney transplant recipients with FD, were enrolled. The post-transplant median follow-up time ranged from 3 to 11.5 years. Overall, the pooled estimated rates of all-cause graft failure, graft failure before death, and allograft rejection were 32.5% (95%CI: 23.9%–42.5%), 14.5% (95%CI: 8.4%–23.7%), and 20.2% (95%CI: 15.4%–25.9%), respectively. In the sensitivity analysis, limited only to the recent studies (year 2001 or newer when ERT became available), the pooled estimated rates of all-cause graft failure, graft failure before death, and allograft rejection were 28.1% (95%CI: 20.5%–37.3%), 11.7% (95%CI: 8.4%–16.0%), and 20.2% (95%CI: 15.5%–26.0%), respectively. The pooled estimated rate of biopsy proven FD recurrence was 11.1% (95%CI: 3.6%–29.4%), respectively. There are no significant differences in the risks of all-cause graft failure (p = 0.10) or mortality (0.48) among recipients with vs. without FD. Conclusions: Despite possible FD recurrence after transplantation of 11.1%, allograft and patient survival are comparable among kidney transplant recipients with vs. without FD. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

34. Recent Advances and Clinical Outcomes of Kidney Transplantation.

Author

Thongprayoon, Charat, Hansrivijit, Panupong, Leeaphorn, Napat, Acharya, Prakrati, Torres-Ortiz, Aldo, Kaewput, Wisit, Kovvuru, Karthik, Kanduri, Swetha R., Bathini, Tarun, and Cheungpasitporn, Wisit

Subjects
KIDNEY transplantation, ELECTRONIC health records, HOMOGRAFTS, RESEARCH & development, KIDNEY failure
Abstract

Recent advances in surgical, immunosuppressive and monitoring protocols have led to the significant improvement of overall one-year kidney allograft outcomes. Nonetheless, there has not been a significant change in long-term kidney allograft outcomes. In fact, chronic and acute antibody-mediated rejection (ABMR) and non-immunological complications following kidney transplantation, including multiple incidences of primary kidney disease, as well as complications such as cardiovascular diseases, infections, and malignancy are the major factors that have contributed to the failure of kidney allografts. The use of molecular techniques to enhance histological diagnostics and noninvasive surveillance are what the latest studies in the field of clinical kidney transplant seem to mainly focus upon. Increasingly innovative approaches are being used to discover immunosuppressive methods to overcome critical sensitization, prevent the development of anti-human leukocyte antigen (HLA) antibodies, treat chronic active ABMR, and reduce non-immunological complications following kidney transplantation, such as the recurrence of primary kidney disease and other complications, such as cardiovascular diseases, infections, and malignancy. In the present era of utilizing electronic health records (EHRs), it is strongly believed that big data and artificial intelligence will reshape the research done on kidney transplantation in the near future. In addition, the utilization of telemedicine is increasing, providing benefits such as reaching out to kidney transplant patients in remote areas and helping to make scarce healthcare resources more accessible for kidney transplantation. In this article, we discuss the recent research developments in kidney transplants that may affect long-term allografts, as well as the survival of the patient. The latest developments in living kidney donation are also explored. [ABSTRACT FROM AUTHOR]

Published
2020
Full Text
View/download PDF

37. Use and outcomes of kidneys from donors with renal angiomyolipoma: A systematic review.

Author

Anton DG, Kovvuru K, Kanduri SR, Aeddula NR, Bathini T, Thongprayoon C, Kaewput W, Wijarnpreecha K, Watthanasuntorn K, Salim SA, Matemavi P, Vaitla P, Rivera FC, and Cheungpasitporn W

Abstract

Background: Renal angiomyolipoma (AML) is the most frequent mesenchymal tumor of the kidney. Although there is a rare possibility of malignant transformation of AML, this risk has not been studied in immunosuppressed patients. The safety of donors with AML and their kidney transplant recipients has not been well established., Methods: A literature search was conducted utilizing MEDLINE, EMBASE, and Cochrane databases from inception through May 15, 2018 (updated on October 2019). We included studies that reported the outcomes of kidney donors with AML or recipients of donor with AML. The protocol for this meta-analysis is registered with PROSPERO (International Prospective Register of Systematic Reviews; no. CRD42018095157)., Results: Fourteen studies with a total of 16 donors with AML were identified. None of the donors had a diagnosis of tuberous sclerosis complex (TSC), pulmonary lymphangioleiomyomatosis (LAM), or epithelioid variant of AML. Donor age ranged from 35 to 77 years, and recipient age ranged from 27 to 62 years. Ninety-two percent of the donors were female. Only 8% were deceased donor renal transplant. The majority underwent ex vivo resection (65%) before transplantation, followed by no resection (18%), and the remaining had in vivo resection. Tumor size varied from 0.4 cm to 7 cm, and the majority (87%) were localized in the right kidney. Follow-up time ranged from 1 to 107 months. Donor creatinine prenephrectomy ranged 0.89-1.1 mg/dL and postnephrectomy creatinine 1.0-1.17 mg/dL. In those who did not have resection of the AML, tumor size remained stable. None of the donors with AML had end-stage renal disease or died at last follow-up. None of the recipients had malignant transformation of AML., Conclusion: These findings are reassuring for the safety of donors with AML (without TSC or LAM) as well as their recipients without evidence of malignant transformation of AML. As such, this can also positively impact the donor pool by increasing the number of available kidneys., Competing Interests: There are no conflicts of interest., (Copyright: © 2021 Urology Annals.)

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results